[1] Ponto KA, Binder H, Diana T, et al. Prevalence, phenotype, and psychosocial well-being in euthyroid/hypothyroid thyroid-associated orbitopathy[J].Thyroid,2015,25(8):942-948.DOI:10.1089/thy.2015.0031.
[2] Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid Eye disease[J].N Engl J Med,2020,382(4):341-352.DOI:10.1056/NEJMoa1910434.
[3] Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of graves orbitopathy[J].Nat Rev Endocrinol,2020,16(2):104-116.DOI:10.1038/s41574-019-0305-4.
[4] Dolman PJ. Dysthyroid optic neuropathy: evaluation and management[J].J Endocrinol Invest,2021,44(3):421-429.DOI:10.1007/s40618-020-01361-y.
[5] Potvin ARGG, Pakdel F, Saeed P. Dysthyroid optic neuropathy[J].Ophthalmic Plast Reconstr Surg,2023,39(6S):S65-S80.DOI:10.1097/IOP.0000000000002555.
[6] Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 european thyroid association/european group on graves' orbitopathy guidelines for the management of graves' orbitopathy[J].Eur Thyroid J,2016,5(1):9-26.DOI:10.1159/000443828.
[7] Rotondo Dottore G, Chiarini R, De Gregorio M, et al. Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves' orbitopathy[J].Endocrine,2017,58(2):386-389.DOI:10.1007/s12020-016-1226-9.
[8] Xu B, Wu D, Ying H, et al. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with graves' disease[J].Turk J Med Sci,2019,49(3):715-722.DOI:10.3906/sag-1808-67.
[9] Marcocci C, Kahaly GJ, Krassas GE, et al. Selenium and the course of mild graves' orbitopathy[J].N Engl J Med,2011,364(20):1920-1931.DOI:10.1056/NEJMoa1012985.
[10] Hall AJH, Topliss DJ. Medical and surgical treatment of thyroid eye disease[J].Intern Med J,2022,52(1):14-20.DOI:10.1111/imj.15067.
[11] Winther KH, Rayman MP, Bonnema SJ, et al. Selenium in thyroid disorders - essential knowledge for clinicians[J].Nat Rev Endocrinol,2020,16(3):165-176.DOI:10.1038/s41574-019-0311-6.
[12] Li X, Li S, Fan W, et al. Recent advances in graves ophthalmopathy medical therapy: a comprehensive literature review[J].Int Ophthalmol,2023,43(4):1437-1449.DOI:10.1007/s10792-022-02537-6.
[13] Rajendram R, Taylor PN, Wilson VJ, et al. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial[J].Lancet Diabetes Endocrinol,2018,6(4):299-309.DOI:10.1016/S2213-8587(18)30021-4.
[14] Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for graves' orbitopathy: efficacy and morbidity[J].J Clin Endocrinol Metab,2011,96(2):320-332.DOI:10.1210/jc.2010-1962.
[15] Zhu W, Ye L, Shen L, et al. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy[J].J Clin Endocrinol Metab,2014,99(6):1999-2007.DOI:10.1210/jc.2013-3919.
[16] Gao G, Dai J, Qian Y, et al. Meta-analysis of methylprednisolone pulse therapy for graves' ophthalmopathy[J].Clin Exp Ophthalmol,2014,42(8):769-777.DOI:10.1111/ceo.12317.
[17] Smith TJ. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy[J].Best Pract Res Clin Endocrinol Metab,2020,34(1):101383.DOI:10.1016/j.beem.2020.101383.
[18] Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy[J].N Engl J Med,2017,376(18):1748-1761.DOI:10.1056/NEJMoa1614949.
[19] Smith TJ. Teprotumumab in thyroid-associated ophthalmopathy: rationale for therapeutic insulin-like growth factor-I receptor inhibition[J].J Neuroophthalmol,2020,40(1):74-83.DOI:10.1097/WNO.0000000000000890.
[20] Smith TJ, Hegedus L. Graves' disease[J].N Engl J Med,2016,375(16):1552-1565.DOI:10.1056/NEJMra1510030.
[21] Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-resistant graves' orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience[J].J Clin Med,2021,10(4):706.DOI:10.3390/jcm10040706.
[22] Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves' orbitopathy[J].Ophthalmic Plast Reconstr Surg,2014,30(2):162-167.DOI:10.1097/IOP.0000000000000037.
[23] Copperman T, Idowu OO, Kersten RC, et al. Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery[J].Ophthalmic Plast Reconstr Surg,2019,35(3):e64-e66.DOI:10.1097/IOP.0000000000001346.
[24] González-García A, Sales-Sanz M. Treatment of graves' ophthalmopathy[J].Med Clin (Barc),2021,156(4):180-186.DOI:10.1016/j.medcli.2020.07.031.
[25] Allison AC. Mechanisms of action of mycophenolate mofetil[J].Lupus,2005,14 Suppl 1:s2-s8.DOI:10.1191/0961203305lu2109oa.
[26] Chakrabarti K, Frame D, Al Abbas M, et al. The use of mycophenolate mofetil area under the curve[J].Curr Opin Rheumatol,2021,33(3):221-232.DOI:10.1097/BOR.0000000000000799.
[27] Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe graves' orbitopathy[J].Clin Endocrinol (Oxf),2017,86(2):247-255.DOI:10.1111/cen.13170.
[28] Kahaly GJ, Riedl M, König J, et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial[J].Lancet Diabetes Endocrinol,2018,6(4):287-298.DOI:10.1016/S2213-8587(18)30020-2.
[29] Bartalena L, Kahaly GJ, Baldeschi L, et al. The 2021 european group on graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43-G67.DOI:10.1530/EJE-21-0479.
[30] Stoynova MA, Shinkov AD, Novoselski MT, et al. Changes in therapeutic response, ocular manifestations of graves' orbitopathy and quality of life during the first year after orbital radiotherapy[J].Int Ophthalmol,2023,43(11):4305-4314.DOI:10.1007/s10792-023-02842-8.
[31] Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy[J].N Engl J Med,1989,321(20):1353-1359.DOI:10.1056/NEJM198911163212002.
[32] Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy[J]. Invest Ophthalmol Vis Sci,2014,55(3):1735-1748.DOI:10.1167/iovs.14-14002.
|
